Triple-negative breast cancer (TNBC) remains one of the most challenging forms of breast cancer to treat because it lacks the estrogen, progesterone and HER2 receptors that enable targeted treatment in other breast cancer subtypes.
EGFR co-targeting and nanotechnology offer new triple-negative breast cancer therapies
Like
Liked
Date:
